Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)

Oncology (Switzerland)

Volumn 89, Issue 2, 2015, Pages 70-78

  Niegisch, Günter ^a   Retz, Margitta ^b   Thalgott, Mark ^b   Balabanov, Stefan ^c   Honecker, Friedemann ^c   Ohlmann, Carsten Henning ^d   Stöckle, Michael ^d   Bögemann, Martin ^e   Vom Dorp, Frank ^f   Gschwend, Jürgen ^b   Hartmann, Arndt ^g   Ohmann, Christian ^a   Albers, Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Chemotherapy; Everolimus; Paclitaxel; Platinum failure; Urothelial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; EVEROLIMUS; GEMCITABINE; HEMOGLOBIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ACNE; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASCITES; ATRIAL FIBRILLATION; BILIARY TRACT INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER INHIBITION; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY SKIN; DYSPNEA; FEMALE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTHYROIDISM; KIDNEY FAILURE; KIDNEY INFECTION; LEUKOPENIA; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; URETER OBSTRUCTION; URINARY TRACT INFECTION; UROGENITAL TRACT CANCER; CLINICAL TRIAL; DRUG EFFECTS; GERMANY; PATHOLOGY; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; EVEROLIMUS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84937522925     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000376551     Document Type: Article

References (30)

1. von der Maase H, Sengelov L, Roberts JT, Ric-ci S, Dogliotti L, Oliver T, Moore MJ, Zim-mermann A, Arning M: Long-term survival results of a randomized trial comparing gem-citabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608.
2. Sternberg CN, de Mulder P, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Du-clos B, Roberts JT, de Balincourt C, Collette L: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50-54.
3. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199.
4. Bellmunt J, Théodore C, Demkov T, Komya-kov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461.
5. Albers P, Park SI, Niegisch G, Fechner G, Steiner U, Lehmann J, Heimbach D, Heiden-reich A, Fimmers R, Siener R: Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22:288-294.
6. Kaya AO, Coskun U, Ozkan M, Sevinc A, Yilmaz AU, Gumus M, Unal OU, Ozdemir NY, Alici S, Berk V, Degerli H, Oner MK, Oz-turk C, Kefeli U, Camci C: Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy. Onkologie 2012; 35:576-580.
7. Joly F, Houédé N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, Rolland F, Fléchon A, Henry-Amar M, Culine S: Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer 2009; 7:E28-E33.
8. O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA: Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 2011; 22:58-78.
9. Voss MH, Molina AM, Motzer RJ: mTOR inhibitors in advanced renal cell carcinoma. He-matol Oncol Clin North Am 2011; 25:835-852.
10. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA: Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28:5110-5115.
11. Sun JM, Kim JR, Do IG, Lee SY, Lee J, Choi YL, Ahn JS, Ahn MJ, Park K: A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. Br J Cancer 2013; 109: 1482-1487.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Tox-icity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
14. Aaronson NK, Ahmedzai S, Bergman B, Bul-linger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
15. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937-940.
16. Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dop-chie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glo-rieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP: Phase II study of evero-limus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012; 23: 2663-2670.
17. Milowsky MI, Iyer G, Regazzi AM, Al-Ah-madie H, Gerst SR, Ostrovnaya I, Gellert LL, Kaplan R, Garcia-Grossman IR, Pendse D, Balar AV, Flaherty AM, Trout A, Solit DB, Ba-jorin DF: Phase II study of everolimus in met-astatic urothelial cancer. BJU Int 2013; 112: 462-470.
18. Gerullis H, Eimer C, Ecke TH, Georgas E, Frei tas C, Kastenholz S, Arndt C, Heusch C, Otto T: A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol 2012; 29:2870-2876.
19. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
20. Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer JU, Tesch H, Gerber B, Höss C, Kümmel S, Mau C, Jackisch C, Khandan F, Costa SD, Krabisch P, Loibl S, Nekljudova V, Untch M, Minckwitz G: Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab-results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013; 49:2284-2293.
21. Niegisch G, Lorch A, Retz M, Siener R, Albers P: Quality of life in patients undergoing pacli-taxel-based second-line treatment of urothe-lial cancer. J Clin Oncol 2014; 32:abstract E15508.
22. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roy-chowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077.
23. Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 2001; 19:2638-2646.
24. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15:1853-1857.
25. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28:1850-1855.
26. Niegisch G, Fimmers R, Siener R, Park SI, Albers P: Prognostic factors in second-line treatment of urothelial cancers with gem-citabine and paclitaxel (German Association of Urological Oncology trial AB20/99). Eur Urol 2011; 60:1087-1096.
27. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507:315-322.
28. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ah-madie H, Scott SN, Janakiraman M, Pirun M
29. Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajo-rin DF, Berger MF, Taylor BS, Solit DB: Genome sequencing identifies a basis for evero-limus sensitivity. Science 2012; 338:221.
30. Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, Gschwend JE, Retz M: S6K1 and 4E-BP1 are independent [sic!] regulated and control cellular growth in bladder cancer. PLoS One 2011; 6:e27509.